Skip to main content
SpringerLink
Log in

Etoricoxib: profile report

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cochrane DJ, Jarvis B, Keating G. Etoricoxib. Drugs 2002; 62 (18): 2637–51

    Article  PubMed  CAS  Google Scholar 

  2. Schnitzer TJ. Etoricoxib: a viewpoint by Thomas J. Schnitzer. Drugs 2002; 62(18): 2652

    Article  Google Scholar 

  3. Roth SH. Etoricoxib: a viewpoint by Sanford H. Roth. Drugs 2002; 62(18): 2652–3

    Article  Google Scholar 

  4. Steinmeyer J. Etoricoxib: a viewpoint by Juergen Steinmeyer. Drugs 2002; 62(18): 2653

    Article  Google Scholar 

  5. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 Feb; 296 (2): 558–66

    PubMed  CAS  Google Scholar 

  6. Patrignani P, Tacconelli S, Capone ML, et al. The selectivity of novel COX-2 inhibitors in human whole blood assays of COX-isozyme activity [abstract]. EULAR 2002 Annual European Congress of Rheumatology; 2002 12–15 Jun; Stockholm

  7. Curtis SP, Maldonado-Cocco J, Lozada B, et al. Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis [abstract no. 955]. Arthritis Rheum 2000 Sep; 43 Suppl.: 226

    Article  Google Scholar 

  8. Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002 Aug; 29 (8): 1623–30

    PubMed  CAS  Google Scholar 

  9. Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002 Sep; 41 (9): 1052–61

    Article  CAS  Google Scholar 

  10. Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18 (2): 49–58

    Article  PubMed  CAS  Google Scholar 

  11. Malmstrom K, Shahane A, Fricke JR, et al. MK-0663, an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model [abstract no. 1393]. Arthritis Rheum 2000 Sep; 43 Suppl. 9: 299

    Google Scholar 

  12. Malmstrom K, Kotey P, Coughlin H, et al. Efficacy of etoricoxib, naproxen sodium, and acetaminophen/codeine in acute dental pain. Clin Pharmacol Ther 2001 Feb; 69 Suppl. 2: 2

    Google Scholar 

  13. Geba GP, Seger W, Adler JL, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: a 3 month placebo-controlled trial [abstract]. EULAR 2002 Annual European Congress of Rheumatology; 2002 12–15 Jun; Stockholm

  14. Geba G, Puopolo A, Birbara C, et al. Treatment of chronic low back pain (LBP) with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: a three-month placebo-controlled trial [abstract no. 647]. J Pain 2002 Apr; 3 Suppl. 1: 12

    Article  Google Scholar 

  15. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002 Jun 22; 324 (7352): 1488–92

    Article  PubMed  CAS  Google Scholar 

  16. Malmstrom K, Kotey P, Cichanowitz N, et al. The effect of etoricoxib, a highly selective COX-2 inhibitor, in primary dysmennorrhea: a randomized, double-blind, crossover study [abstract no. 783]. J Pain 2002 Apr; 3 Suppl.: 46

    Google Scholar 

  17. Curtis SP, Lee M, Ng J, et al. Fewer upper-GI perforations, ulcers and bleeds (PUBS) with etoricoxib than with nonselective cyclooxygenase inhibitors (NSAIDS) [abstract]. EULAR 2002 Annual European Congress of Rheumatology; 2002 12–15 Jun; Stockholm

  18. Roth SH. A new role for opioids in the treatment of arthritis. Drugs 2002; 62 (2): 255–63

    Article  PubMed  CAS  Google Scholar 

  19. Roth SH. Arthritis therapy: a better time, a better day. Rheumatology (Oxford) 2001 Jun; 40 (6): 603–6

    Article  CAS  Google Scholar 

  20. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res 2000; 2 (5): 379–85

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

    Thomas J. Schnitzer

  2. Arizona Research and Education Ltd, Phoenix, Arizona, USA

    Sanford H. Roth

  3. University Medical Center, Justus-Liebig-University, Giessen, Germany

    Juergen Steinmeyer

Authors
  1. Thomas J. Schnitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanford H. Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juergen Steinmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schnitzer, T.J., Roth, S.H. & Steinmeyer, J. Etoricoxib: profile report. Drugs Ther. Perspect 19, 5–7 (2003). https://doi.org/10.2165/00042310-200319040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319040-00002

Keywords

Search

Navigation